On August 24, 2010, the Los Angeles Times reported that a new study shows that Actos and Avandia have about the same risks for cardiovascular injury. The new study of more than 36,000 diabetics, done by researchers at health insurer WellPoint Inc, compared the risk of heart attacks, heart failure and death for an average of 14 months of treatment, and for a year and a half after treatment. The researchers found the risks of death or having a heart attack, heart failure or both were the same, about 4 percent, for patients taking either Avandia, known generically as rosiglitazone, or Takeda Pharmaceutical Co's Actos, known generically as pioglitazone.

How can Whatley Drake and Kallas help me?

• Cases are being filed against the manufacturer of these products for injuries caused to innocent consumers. Our firm prides itself in going beyond the recovery of money to achieve meaningful change that makes a difference not only to our clients but to our society as a whole. We seek to improve the warnings on products such as these so that future consumers are aware of associated risks and can make informed decisions. If you or someone you know took Actos and experienced problems with heart attack, stroke, or death, please contact our firm.
•  

Read the MedWatch Safety Alert, including links to the Drug Safety Communication and FDA News Release.
 
Read the L.A. Times Article on the risks posed by Actos.

To discuss a potential case, please call us at 1(800) 922-4851 or contact Jack Drake, or Ashley Cranford.